PMID- 27721250
OWN - NLM
STAT- MEDLINE
DCOM- 20170316
LR  - 20181202
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 12
IP  - Supplement
DP  - 2016 Oct
TI  - Adjuvant therapy with heparin in patients with lung cancer without indication for 
      anticoagulants: A systematic review of the literature with meta-analysis.
PG  - 37-42
LID - 10.4103/0973-1482.191627 [doi]
AB  - BACKGROUND: The effect of heparin in improving cancer survival has gained 
      increasing attention over the past decades. Several clinical trials have 
      evaluated the role of heparin on survival outcome and its safety profile in lung 
      cancer patients. Thus, we performed a systematic review and meta-analysis from 
      the results of randomized controlled trials (RCTs) to assess the efficacy and 
      safety of heparin in patients with lung cancer without indication for 
      anticoagulants. METHODS: We searched PubMed, Embase, and The Cochrane Central 
      Register of Controlled Trials databases for relevant studies. The inclusion 
      criteria used were patients with lung cancer without a concurrent diagnosis of 
      venous thromboembolism (VTE) and were treated with low-molecular-weight heparin 
      (LMWH) or unfractionated heparin (UFH). The outcomes included survival outcome, 
      VTE, bleeding, major bleeding, and thrombocytopenia. The results were presented 
      as hazard ratio (HR) and relative risk (RR), and the STATA 12.0 package was used 
      for comprehensive quantitative analysis. RESULTS: A total of 6 studies with 753 
      cases and 640 controls were included for the final analysis. The meta-analysis 
      showed significant differences in survival with an HR of 0.71 (95% confidence 
      interval [CI] 0.60-0.84), particularly in limited-stage small cell lung cancer 
      (SCLC) with an HR of 0.57 (95% CI 0.43-0.77), and also in VTE (RR 0.46; 95% CI 
      0.27-0.80) when heparin was compared with placebo or no anticoagulant. There were 
      no significant differences in risks for bleeding (RR 1.53; 95% CI 0.96-2.45), 
      major bleeding (RR 1.43; 95% CI 0.59-3.45), and thrombocytopenia (RR 0.86; 95% CI 
      0.66-1.12). CONCLUSION: Administration of heparin (mainly LMWH) as primary 
      thromboprophylaxis for lung cancer patients without indication for anticoagulants 
      was associated with a significant survival benefit, particularly in limited-stage 
      SCLC.
FAU - Yu, Yuman
AU  - Yu Y
AD  - Department of Pulmonary Medicine, Hangzhou Normal University, The Affiliated 
      Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang, China.
FAU - Lv, Qun
AU  - Lv Q
AD  - Department of Pulmonary Medicine, Hangzhou Normal University, The Affiliated 
      Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang, China.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Lan, Fen
AU  - Lan F
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Dai, Yifan
AU  - Dai Y
AD  - Department of Pulmonary Medicine, Hangzhou Normal University, The Affiliated 
      Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Hemorrhage/etiology/prevention & control
MH  - Heparin/*administration & dosage/adverse effects
MH  - Humans
MH  - Lung Neoplasms/complications/*drug therapy/mortality
MH  - Odds Ratio
MH  - Survival Analysis
MH  - Thrombocytopenia/etiology
MH  - Thromboembolism/etiology/prevention & control
MH  - Treatment Outcome
EDAT- 2016/10/11 06:00
MHDA- 2017/03/17 06:00
CRDT- 2016/10/11 06:00
PHST- 2016/10/11 06:00 [entrez]
PHST- 2016/10/11 06:00 [pubmed]
PHST- 2017/03/17 06:00 [medline]
AID - JCanResTher_2016_12_5_37_191627 [pii]
AID - 10.4103/0973-1482.191627 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2016 Oct;12(Supplement):37-42. doi: 10.4103/0973-1482.191627.